Merck & Co Inc

NYSE:MRK   11:03:26 AM EDT
-0.43 (-0.46%)
Products, Regulatory

Merck’S Keytruda® (Pembrolizumab) Significantly Improved Disease-Free Survival Vs Placebo In Patients With Stage Ib-IIIa Non-Small Cell Lung Cancer Regardless Of Pd-L1 Expression

Published: 03/17/2022 18:25 GMT
Merck & Co Inc (MRK) - Merck’s Keytruda® (pembrolizumab) Significantly Improved Disease-free Survival (dfs) Versus Placebo As Adjuvant Therapy in Patients With Stage Ib-iiia Non-small Cell Lung Cancer (nsclc) Regardless of Pd-l1 Expression.
Merck - First Phase 3 Study to Demonstrate Statistically Significant Improvement in Dfs in Adjuvant Setting for Patients With Stage Ib-iiia Nsclc Regardless of Pd-l1 Expression.
Merck & Co Inc - Safety Profile of Keytruda in This Study Was Consistent With That Observed in Previously Reported Studies.
Merck - in Addition to Keynote-091, 5 Other Trials Evaluating Keytruda-based Regimen in Patients With Earlier Stages of Cancer Met Primary Endpoint.